Performance of broad-spectrum targeted next-generation sequencing in lower respiratory tract infections in ICU patients a prospective observational study summary

What is PACUPod: Critical Care?

PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across critical care and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.

Britany: Welcome back to PACULit. Today, we’re discussing a prospective observational study by Chen and colleagues, published in 2025, which evaluates broad-spectrum targeted next-generation sequencing, or bstNGS, for diagnosing lower respiratory tract infections in intensive care unit patients. Seth, lower respiratory tract infections remain a major challenge in critical care, don’t they?

Seth: Absolutely, Britany. Hospital-acquired pneumonia and ventilator-associated pneumonia cause significant morbidity and mortality among ICU patients. The critical issue is timely and accurate identification of the causative pathogens. Traditional culture methods often have low sensitivity and slow turnaround times, which delay targeted antimicrobial therapy.

Britany: Metagenomic next-generation sequencing, or mNGS, has improved pathogen detection, but it has limitations. Its untargeted approach generates vast and complex data, and the associated costs and technical demands limit its routine clinical use.

Seth: That’s why bstNGS is particularly intriguing. It combines broad pathogen coverage with improved accuracy and clinical applicability. The panel used in this study covers one thousand eight hundred seventy-two pathogens, which is impressively comprehensive.

Britany: This study fills an important knowledge gap by directly comparing bstNGS with mNGS and traditional culture in ICU patients with suspected lower respiratory tract infections. It also examines how host factors, such as immunocompromised status, affect diagnostic yield, which is critical given the vulnerability of these patients.

Seth: The study enrolled one hundred fifty adult ICU patients undergoing bronchoalveolar lavage, or BAL, for suspected lower respiratory tract infections, including hospital-acquired and ventilator-associated pneumonia. Inclusion criteria were straightforward: adult ICU patients with clinical suspicion of LRTI requiring BAL for microbiological diagnosis.

Britany: While the exclusion criteria were not detailed, presumably patients without BAL samples or with incomplete specimens were excluded. The prospective design allowed direct comparison of bstNGS, mNGS, and culture on the same samples, which strengthens the validity of the findings.

Seth: The primary outcomes were pathogen detection rates and diagnostic accuracy. Secondary outcomes included clinical impact, measured by antibiotic treatment success correlated with pathogen detection. The study also explored the effects of pathogen load and immunocompromised status on diagnostic performance.

Britany: Key findings showed that bstNGS detected ninety-six point three three percent of microbes identified by mNGS and ninety-one point one five percent of those found by culture. Detection rates were eighty-seven point three three percent for bstNGS, eighty-two percent for mNGS, and forty-six percent for culture—a substantial improvement.

Seth: Diagnostic accuracy was ninety point six seven percent for bstNGS, significantly higher than eighty-six percent for mNGS and forty-nine point three three percent for culture. The p-values were less than zero point zero five for bstNGS versus mNGS and less than zero point zero zero zero one for bstNGS versus culture, indicating strong statistical significance.

Britany: Importantly, bstNGS effectively detected lower pathogen loads, which is crucial because early or low-burden infections can be missed by traditional methods, potentially delaying therapy.

Seth: However, immunocompromised patients had reduced bstNGS detection efficiency, with a p-value of zero point zero four. This aligns with existing literature showing that immune status impacts diagnostic yield, possibly due to altered microbial loads or atypical pathogens in these hosts.

Britany: Clinically, this means we must interpret next-generation sequencing results cautiously in immunocompromised patients and consider adjunctive diagnostics or repeat testing. More research is needed to optimize NGS approaches in this subgroup.

Seth: Regarding clinical impact, patients with pathogens detected by bstNGS had better antibiotic treatment success—eighty-nine point six eight percent versus sixty-two point five percent in those without pathogen detection. The odds ratio was seven point five three, with a p-value of zero point zero two, indicating a strong association.

Britany: This suggests that bstNGS-guided therapy improves outcomes by enabling precise antimicrobial selection and supports antimicrobial stewardship by reducing unnecessary broad-spectrum antibiotic use.

Seth: Strengths of the study include its prospective design, direct comparison of three diagnostic methods, and correlation with clinical outcomes. The broad pathogen panel covering nearly two thousand organisms is another highlight.

Britany: Limitations include the modest sample size of one hundred fifty patients, which may limit generalizability. It was a single-center ICU study, so multicenter validation is necessary.

Seth: Additionally, the reduced detection efficiency in immunocompromised patients warrants further study. The study did not specify the types of immunocompromised conditions or therapies, which could influence diagnostic performance.

Britany: Related research includes a 2023 study by Heitz and colleagues, which demonstrated that mNGS on bronchoalveolar lavage fluid detects pathogens missed by culture in ICU pneumonia patients, reinforcing the sensitivity of next-generation sequencing.

Seth: Li and Pan, in 2024, showed the value of mNGS in pneumonia-derived sepsis, a severe subset of ICU infections. These studies support the utility of NGS in critical illness.

Britany: Zhao and colleagues, in 2024 and 2025, focused on immunocompromised ICU patients with severe pneumonia, confirming mNGS’s usefulness but noting that diagnostic accuracy can be affected by immune suppression.

Seth: A meta-analysis by Liu and colleagues highlighted diagnostic differences between immunocompetent and immunocompromised hosts, emphasizing the need for tailored diagnostic strategies.

Britany: Clinically, integrating bstNGS could enhance pathogen detection and guide precise therapy, improving patient outcomes and supporting antimicrobial stewardship.

Seth: However, clinicians should consider limitations in immunocompromised patients and interpret results alongside clinical context and other diagnostic modalities. Cost and turnaround time remain important factors for implementation.

Britany: Speaking of turnaround time, the study reported that bstNGS results were available within twenty-four to thirty-six hours, which is faster than traditional culture methods that can take up to seventy-two hours or more. Seth, how significant is this in critical care?

Seth: That is a crucial point, Britany. In the intensive care unit, every hour counts when managing infections. Faster pathogen identification allows clinicians to tailor antibiotic therapy sooner, potentially reducing the duration of broad-spectrum antibiotic use and limiting the development of resistance. This rapid turnaround can also help avoid unnecessary treatments when no pathogen is detected.

Britany: Exactly. With the increasing global threat of antimicrobial resistance, tools like bstNGS that support timely, targeted therapy are invaluable. Plus, the ability to detect a wide range of pathogens—including bacteria, viruses, fungi, and atypical organisms—in a single test streamlines diagnostics.

Seth: Another consideration is the cost-effectiveness of bstNGS. While next-generation sequencing technologies have historically been expensive, the study suggests that improved diagnostic yield and clinical impact may offset costs by reducing ICU length of stay and complications related to inappropriate antibiotic use.

Britany: That balance is important. Investing in advanced diagnostics upfront could lead to downstream savings and better patient outcomes. However, widespread adoption will require health systems to carefully evaluate these factors.

Seth: Also, as you mentioned earlier, the study used bronchoalveolar lavage fluid, which is invasive. Future research validating bstNGS on less invasive samples, such as sputum or endotracheal aspirates, could expand its use, especially in patients who cannot tolerate bronchoscopy.

Britany: Yes, and combining bstNGS with host response biomarkers might further enhance diagnostic accuracy. For example, integrating procalcitonin levels or inflammatory markers could help differentiate colonization from true infection.

Seth: That is a promising avenue. Overall, bstNGS represents a significant step forward in infectious disease diagnostics within critical care, but integrating it into clinical workflows will require multidisciplinary collaboration.

Britany: Another clinical pearl is that bstNGS can detect polymicrobial infections and resistant organisms more reliably than culture, which informs combination therapy decisions.

Seth: Knowing exact pathogens and resistance profiles helps avoid unnecessary broad-spectrum agents, reducing adverse effects and drug interactions, especially in polypharmacy ICU patients.

Britany: Looking ahead, multicenter trials are needed to validate bstNGS and assess its impact on mortality and length of stay. Research should also focus on optimizing protocols for immunocompromised hosts.

Seth: Integrating bstNGS into antimicrobial stewardship programs could enable rapid de-escalation or escalation of therapy based on precise microbiological data.

Britany: To summarize, Chen and colleagues provide strong evidence that bstNGS outperforms mNGS and culture in detecting pathogens in ICU lower respiratory tract infections and correlates with improved antibiotic treatment success.

Seth: While challenges remain, especially in immunocompromised patients, bstNGS is a promising diagnostic advance that could transform the management of complex infections.

Britany: Thanks for the insightful discussion, Seth. And thank you all for tuning in to PACULit. Stay curious and informed—we will catch you next time.

Seth: Thanks, Britany. Take care, everyone.